검색
Jazz Pharmaceuticals PLC
JAZZ관심 목록에 추가
252.860USD
-5.520-2.14%
종가 07-31 16:00（ET）시세는 15분 지연됩니다
15.53B시가총액
613.23P/E TTM
자세한 내용은 Jazz Pharmaceuticals PLC 회사
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Jazz Pharmaceuticals PLC 정보
종목 코드 JAZZ
회사 이름Jazz Pharmaceuticals PLC
상장일Jan 18, 2012
CEOGala (Renee D)
직원 수2800
유형Ordinary Share
회계 연도 종료Jan 18
주소Fifth Floor, Waterloo Exchange
도시DUBLIN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Ireland
우편 번호- -
전화35316347800
웹사이트https://www.jazzpharma.com/
종목 코드 JAZZ
상장일Jan 18, 2012
CEOGala (Renee D)
Jazz Pharmaceuticals PLC의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
327.80K
-1.83%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.05K
-10.25%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
45.42K
-8.29%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.75K
-18.69%
Ms. Samantha Pearce
Ms. Samantha Pearce
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
20.26K
-12.47%
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Director
Independent Director
17.65K
+30.00%
Ms. Anne O'Riordan
Ms. Anne O'Riordan
Independent Director
Independent Director
16.50K
+21.25%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
10.84K
+32.36%
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Seamus C. Mulligan
Mr. Seamus C. Mulligan
Independent Director
Independent Director
1.28M
+0.54%
Mr. Bruce C. Cozadd
Mr. Bruce C. Cozadd
Chairman of the Board
Chairman of the Board
327.80K
-1.83%
Ms. Renee D. Gala
Ms. Renee D. Gala
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.05K
-10.25%
Dr. Robert Iannone, M.D.
Dr. Robert Iannone, M.D.
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
Executive Vice President, Global Head - Research and Development, Chief Medical Officer
45.42K
-8.29%
Mr. Philip L. Johnson
Mr. Philip L. Johnson
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
24.89K
-13.43%
Ms. Neena M. Patil, J.D.
Ms. Neena M. Patil, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
20.75K
-18.69%
자주 묻는 질문
Jazz Pharmaceuticals PLC의 상위 5대 주주는 누구인가요?
Jazz Pharmaceuticals PLC의 상위 5대 주주는 다음과 같습니다: Mr. Seamus C. Mulligan
Jazz Pharmaceuticals PLC(JAZZ)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Jazz Pharmaceuticals PLC의 주식을 보유한 기관은 총 1229곳이며, 이들이 보유한 주식의 총 가치는 약 70.31M로 전체 발행 주식의 112.06%를 차지합니다. 이는 2025Q4 대비 -754072.00 증가한 수치입니다.
Jazz Pharmaceuticals PLC의 최대 수익원은 무엇인가요?
2026Q1 기준, Jazz Pharmaceuticals PLC의 Xywav 부문이 가장 높은 매출을 기록했으며, 금액은 1.66B로 전체 매출의 38.83%를 차지했습니다.